Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.
Combining a blood DNA test with standard factors better predicts which early colorectal cancers can be safely removed without surgery.
The COSMOS-CRC multicenter prospective study demonstrated that integrating cfDNA profiling with standard clinicopathologic factors creates a superior predictive model for lymph node metastasis risk in T1 colorectal cancer. The composite approach could help identify T1 CRC patients who can safely undergo endoscopic resection, reducing unnecessary radical surgery and associated morbidity.
What the study was
- Study design
- Multicenter Prospective Cohort Study
- Population
- T1 colorectal cancer patients at multiple Japanese cancer centers (COSMOS-CRC study)
- Category
- Early Detection
- Maturity
- Validated
- Journal
- JCO precision oncology
Why it surfaced
COSMOS-CRC multicenter prospective study in JCO PO; cfDNA+clinicopathologic model for T1 CRC management is directly practice-informing; Yoshino/Nakamura labs (NCCH Japan).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.